229 related articles for article (PubMed ID: 34695195)
1. PLCG1 is required for AML1-ETO leukemia stem cell self-renewal.
Schnoeder TM; Schwarzer A; Jayavelu AK; Hsu CJ; Kirkpatrick J; Döhner K; Perner F; Eifert T; Huber N; Arreba-Tutusaus P; Dolnik A; Assi SA; Nafria M; Jiang L; Dai YT; Chen Z; Chen SJ; Kellaway SG; Ptasinska A; Ng ES; Stanley EG; Elefanty AG; Buschbeck M; Bierhoff H; Brodt S; Matziolis G; Fischer KD; Hochhaus A; Chen CW; Heidenreich O; Mann M; Lane SW; Bullinger L; Ori A; von Eyss B; Bonifer C; Heidel FH
Blood; 2022 Feb; 139(7):1080-1097. PubMed ID: 34695195
[TBL] [Abstract][Full Text] [Related]
2. Definition of a small core transcriptional circuit regulated by AML1-ETO.
Stengel KR; Ellis JD; Spielman CL; Bomber ML; Hiebert SW
Mol Cell; 2021 Feb; 81(3):530-545.e5. PubMed ID: 33382982
[TBL] [Abstract][Full Text] [Related]
3. AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/β-catenin signaling pathway.
Zhang Y; Wang J; Wheat J; Chen X; Jin S; Sadrzadeh H; Fathi AT; Peterson RT; Kung AL; Sweetser DA; Yeh JR
Blood; 2013 Jun; 121(24):4906-16. PubMed ID: 23645839
[TBL] [Abstract][Full Text] [Related]
4. Cell-intrinsic depletion of Aml1-ETO-expressing pre-leukemic hematopoietic stem cells by K-Ras activating mutation.
Di Genua C; Norfo R; Rodriguez-Meira A; Wen WX; Drissen R; Booth CAG; Povinelli B; Repapi E; Gray N; Carrelha J; Kettyle LM; Jamieson L; Neo WH; Thongjuea S; Nerlov C; Mead AJ
Haematologica; 2019 Nov; 104(11):2215-2224. PubMed ID: 30975913
[TBL] [Abstract][Full Text] [Related]
5. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
[TBL] [Abstract][Full Text] [Related]
6. An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.
Zaidi SK; Perez AW; White ES; Lian JB; Stein JL; Stein GS
Oncotarget; 2017 Jun; 8(25):39994-40005. PubMed ID: 28611288
[TBL] [Abstract][Full Text] [Related]
7. Immortalization of human AE pre-leukemia cells by hTERT allows leukemic transformation.
Lin S; Wei J; Wunderlich M; Chou FS; Mulloy JC
Oncotarget; 2016 Aug; 7(35):55939-55950. PubMed ID: 27509060
[TBL] [Abstract][Full Text] [Related]
8. A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells.
Gao XN; Lin J; Ning QY; Gao L; Yao YS; Zhou JH; Li YH; Wang LL; Yu L
PLoS One; 2013; 8(2):e55481. PubMed ID: 23390536
[TBL] [Abstract][Full Text] [Related]
9. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1.
Nishida S; Hosen N; Shirakata T; Kanato K; Yanagihara M; Nakatsuka S; Hoshida Y; Nakazawa T; Harada Y; Tatsumi N; Tsuboi A; Kawakami M; Oka Y; Oji Y; Aozasa K; Kawase I; Sugiyama H
Blood; 2006 Apr; 107(8):3303-12. PubMed ID: 16380455
[TBL] [Abstract][Full Text] [Related]
10. AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia.
Dunne J; Gascoyne DM; Lister TA; Brady HJ; Heidenreich O; Young BD
Cancer Res; 2010 May; 70(10):3985-95. PubMed ID: 20460523
[TBL] [Abstract][Full Text] [Related]
11. Targeting miR-193a-AML1-ETO-β-catenin axis by melatonin suppresses the self-renewal of leukaemia stem cells in leukaemia with t (8;21) translocation.
Zhou B; Ye H; Xing C; Liang B; Li H; Chen L; Huang X; Wu Y; Gao S
J Cell Mol Med; 2019 Aug; 23(8):5246-5258. PubMed ID: 31119862
[TBL] [Abstract][Full Text] [Related]
12. UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.
Goyama S; Schibler J; Gasilina A; Shrestha M; Lin S; Link KA; Chen J; Whitman SP; Bloomfield CD; Nicolet D; Assi SA; Ptasinska A; Heidenreich O; Bonifer C; Kitamura T; Nassar NN; Mulloy JC
Leukemia; 2016 Mar; 30(3):728-39. PubMed ID: 26449661
[TBL] [Abstract][Full Text] [Related]
13. MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML.
Vegi NM; Klappacher J; Oswald F; Mulaw MA; Mandoli A; Thiel VN; Bamezai S; Feder K; Martens JHA; Rawat VPS; Mandal T; Quintanilla-Martinez L; Spiekermann K; Hiddemann W; Döhner K; Döhner H; Stunnenberg HG; Feuring-Buske M; Buske C
Cell Rep; 2016 Jul; 16(2):498-507. PubMed ID: 27346355
[TBL] [Abstract][Full Text] [Related]
14. Co-expression of AML1-ETO and PML-RARa following treatment of de novo acute myeloid leukemia with AML1-ETO.
Zhang S; Zhou W; Li Y; Yu S; Xue M; Qiao Y; Jian J; Liu B; Wang D
Leuk Lymphoma; 2019 May; 60(5):1316-1319. PubMed ID: 30328750
[No Abstract] [Full Text] [Related]
15. Pontin is a critical regulator for AML1-ETO-induced leukemia.
Breig O; Bras S; Martinez Soria N; Osman D; Heidenreich O; Haenlin M; Waltzer L
Leukemia; 2014 Jun; 28(6):1271-9. PubMed ID: 24342949
[TBL] [Abstract][Full Text] [Related]
16. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis.
Sun XJ; Wang Z; Wang L; Jiang Y; Kost N; Soong TD; Chen WY; Tang Z; Nakadai T; Elemento O; Fischle W; Melnick A; Patel DJ; Nimer SD; Roeder RG
Nature; 2013 Aug; 500(7460):93-7. PubMed ID: 23812588
[TBL] [Abstract][Full Text] [Related]
17. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia.
Miyamoto T; Nagafuji K; Akashi K; Harada M; Kyo T; Akashi T; Takenaka K; Mizuno S; Gondo H; Okamura T; Dohy H; Niho Y
Blood; 1996 Jun; 87(11):4789-96. PubMed ID: 8639850
[TBL] [Abstract][Full Text] [Related]
18. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice.
Schessl C; Rawat VP; Cusan M; Deshpande A; Kohl TM; Rosten PM; Spiekermann K; Humphries RK; Schnittger S; Kern W; Hiddemann W; Quintanilla-Martinez L; Bohlander SK; Feuring-Buske M; Buske C
J Clin Invest; 2005 Aug; 115(8):2159-68. PubMed ID: 16025155
[TBL] [Abstract][Full Text] [Related]
19. A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program.
Lin S; Ptasinska A; Chen X; Shrestha M; Assi SA; Chin PS; Imperato MR; Aronow BJ; Zhang J; Weirauch MT; Bonifer C; Mulloy JC
Blood; 2017 Sep; 130(10):1213-1222. PubMed ID: 28710059
[TBL] [Abstract][Full Text] [Related]
20. YTHDF2 is a potential target of AML1/ETO-HIF1α loop-mediated cell proliferation in t(8;21) AML.
Chen Z; Shao YL; Wang LL; Lin J; Zhang JB; Ding Y; Gao BB; Liu DH; Gao XN
Oncogene; 2021 Jun; 40(22):3786-3798. PubMed ID: 33958724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
